Skip to main content

Table 2 Effects of 4- and 12-week treatment of pitavastatin (PTV) and atorvastatin (ATV) on lipid profiles, systemic biomarkers and endothelial progenitor cells

From: Effects of pitavastatin versus atorvastatin on the peripheral endothelial progenitor cells and vascular endothelial growth factor in high-risk patients: a pilot prospective, double-blind, randomized study

  Baseline 4 weeks 12 weeks PTV# ATV#
  PTV ATV P-value PTV ATV P-value PTV ATV P-value P-value P-value
WBC (/cumm) 6223 ± 1790 7184 ± 1563 0.16 6784 ± 2106 7238 ± 1180 0.50 6338 ± 1809 6930 ± 1245 0.34 0.73 0.82
Glucose (mmol/L) 6.98 ± 1.39 6.28 ± 1.04 0.16 7.12 ± 1.71 6.54 ± 1.23 0.39 7.58 ± 2.54 6.54 ± 1.05 0.18 0.71 0.80
HOMA-IR 1.9 ± 1.2 2.0 ± 1.0 0.78     5.2 ± 4.8 3.9 ± 2.8 0.41 0.05 <0.05
hs-CRP (mg/dL) 0.18 ± 0.18 0.35 ± 0.37 0.16 0.17 ± 0.11 0.16 ± 0.19 0.90 0.20 ± 0.20 0.17 ± 0.20 0.88 0.93 0.17
TC (mmol/L) 5.20 ± 0.69 5.24 ± 0.64 0.89 3.73 ± 0.53 3.62 ± 0.36 0.53 3.65 ± 0.52 3.56 ± 0.37 0.58 <0.05 <0.05
TG (mmol/L) 1.53 ± 0.71 1.72 ± 0.59 0.46 1.25 ± 0.58 1.26 ± 0.28 0.94 1.15 ± 0.51 1.22 ± 0.39 0.72 0.26 <0.05
LDL-c (mmol/L) 3.70 ± 0.55 3.82 ± 0.85 0.68 2.12 ± 0.46 2.19 ± 0.45 0.68 2.14 ± 0.33 2.09 ± 0.51 0.76 <0.05 <0.05
HDL-c (mmol/L) 1.25 ± 0.25 1.18 ± 0.19 0.38 1.29 ± 0.33 1.18 ± 0.18 0.32 1.25 ± 0.28 1.19 ± 0.20 0.58 0.92 0.96
NOx (μmol/L) 70.8 ± 42.5 78.5 ± 96.8 0.80 75.3 ± 66.1 80.6 ± 62.9 0.85 79.5 ± 86.1 68.9 ± 46.4 0.71 0.95 0.91
IL-10 (pg/ml) 1.8 ± 1.2 1.5 ± 0.8 0.48 2.1 ± 1.6 2.1 ± 1.4 0.91 2.07 ± 1.6 1.7 ± 1.8 0.57 0.87 0.55
TNF-α (pg/ml) 3.6 ± 1.7 4.0 ± 2.8 0.67 3.3 ± 1.8 4.5 ± 2.8 0.22 2.8 ± 0.8 4.3 ± 3.2 0.12 0.45 0.91
ADMA (μmol/L) 0.61 ± 0.10 0.68 ± 0.10 0.09     0.56 ± 0.12 0.53 ± 0.12 0.55 0.25 <0.05
SDF-1α (pg/ml) 2619.9 ± 640.5 2851.4 ± 669.1 0.38 2673.5 ± 774.6 3043.3 ± 733.5 0.24 2603.6 ± 757.1 3085.5 ± 701.1 0.16 0.98 0.668
VEGF (pg/ml) 74.33 ± 32.26 69.86 ± 31.53 0.72 118.36 ± 50.05 67.65 ± 42.85 0.01 98.65 ± 46.64 74.04 ± 29.33 0.12 <0.05 0.898
EPC level (%)            
CD34+KDR+ 0.021 ± 0.015 0.039 ± 0.039 0.16 0.035 ± 0.031 0.029 ± 0.024 0.59 0.054 ± 0.044 0.043 ± 0.029 0.45 <0.05 0.57
  1. Values are mean ± standard deviation. #: Difference between baseline, 4 weeks and 12 weeks of treatment in the same group. WBC: white blood cell; HOMA-IR: Homeostasis model of assessment-insulin resistance; TC: total cholesterol; TG: Triglyceride; LDL-c: low-density lipoprotein cholesterol; HDL-c: high-density lipoprotein cholesterol; hs-CRP: high sensitivity C-reactive protein; NOx: total nitric oxide; IL-10: interleukin-10; TNF-α: tumor necrosis factor-α; ADMA: asymmetric dimethylarginine; SDF-1α: stromal cell-derived factor-1α; VEGF: vascular endothelial growth factor; EPC: endothelial progenitor cell.